CACLP 2026 will debut the Medical Research Pavilion as a dedicated platform designed to bridge scientific research with clinical practice within the healthcare system.

The Chinese University of Hong Kong (CUHK) said Wednesday that it has struck a deal with startup MicroSigX Biotech Diagnostic to offer an investigational microbiome test for autism to 200 eligible children under a pilot project.

Exact Sciences is building evidence on the ability of its Oncodetect minimal residual disease (MRD) test to determine the risk of distant recurrence in breast cancer patients in the hopes of expanding its adoption and reimbursement in this setting.

Siemens Healthineers and the National University Hospital (NUH) Singapore have announced a strategic research collaboration to advance diagnostic solutions for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects nearly 40% of adults in Singapore — a prevalence that is higher than the global average of 30.05%.

Nineteen companies reported R&D-to-revenue ratios above 20% in H1 2025. Roughly 42.5% of IVD companies increased their R&D spending compared to revenue.

US drugmaker Merck has scrapped a £1bn London research centre and will lay off more than 100 scientific staff, as the industry accuses ministers of making the UK uncompetitive and paying too little for medicines.

On June 4 2025, Elsevier officially released the 2024 CiteScore, a key metric used to assess the impact of academic journals. VIEW, jointly sponsored by China Professional Community of Experimental Medicine (CPCEM) and published by John Wiley & Sons, achieved a CiteScore of 14.5 for 2024.

Tecan Group (SIX Swiss Exchange: TECN) today announced an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS, a subsidiary of the global life sciences and diagnostics company, Revvity Inc. The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits.

Manufacturing investments have taken center stage in recent years — from some pharma giants ramping up GLP-1 manufacturing capacity to meet soaring demand to other companies focusing on advanced capabilities that could ensure an adequate supply of vaccines.

A respected organization acclaimed for their groundbreaking work with neurological diseases, C2N Diagnostics, LLC, is partnering with The Michael J. Fox Foundation For Parkinson’s Research (MJFF) to better understand the connections amongst neurodegenerative conditions, Alzheimer’s disease (AD) and neuronal a-synuclein disease (NSD), which encompasses Parkinson’s disease (PD), Lewy body dementia (LBD) and REM behavior disorder (RBD).